FTRE
Fortrea Holdings Inc
NASDAQ · Life Sciences Tools & Services
$14.65
+0.85 (+6.16%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 2.78B | 2.90B | 1.30B | 1.34B | 1.39B |
| Net Income | -339,144,960 | -318,279,941 | 47.15M | 52.33M | 61.93M |
| EPS | — | — | — | — | — |
| Profit Margin | -12.2% | -11.6% | 3.6% | 3.9% | 4.5% |
| Rev Growth | -4.1% | -4.1% | +9.5% | +7.6% | +19.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 306.05M | 306.05M | 581.19M | 574.49M | 632.75M |
| Total Equity | 370.78M | 370.78M | 947.83M | 884.45M | 884.57M |
| D/E Ratio | 0.83 | 0.83 | 0.61 | 0.65 | 0.72 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -57,093,960 | -56,558,145 | 70.91M | 75.93M | 85.51M |
| Free Cash Flow | — | — | 48.26M | 62.53M | 81.90M |